Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Optellum, a lung health start-up in Oxford, aims to redefine early interception of lung cancer using artificial intelligence (AI) decision support software.

CT scan image of lungs

Optellum, a lung-health AI company in Oxford has entered a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson. Through the collaboration, Optellum will apply its AI-powered clinical decision support platform with the goal of increasing lung cancer survival rates through early intervention and prevention.

Optellum was co-founded by Oxford cancer researcher Prof. Sir Michael Brady (Department of Oncology) with the mission of seeing every lung disease patient diagnosed and treated at the earliest possible stage, and cured.

Read the full story on the Oxford Cancer website.